Intelgenx Technologies Revenue Growth Rates (IGXT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intelgenx Technologies Corp   (IGXT)
 

IGXT's Revenue Growth by Quarter and Year

Intelgenx Technologies 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IGXT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.17
FY 0.17

IGXTs Annual Revenue
Intelgenx Technologies 's Revenue in the fiscal year 2023 $ 1.04 millions
Intelgenx Technologies 's Revenue in the fiscal year 2022 $ 0.95 millions
Intelgenx Technologies 's Revenue in the fiscal year 2021 $ 1.54 millions
Intelgenx Technologies 's Revenue in the fiscal year 2020 $ 1.54 millions
Intelgenx Technologies 's Revenue in the fiscal year 2019 $ 0.74 millions




IGXT Revenue first quarter 2024 Y/Y Growth Comment
Intelgenx Technologies Corp reported Revenue growth of 8.75% year on year in the first quarter 2024, to $ 0.17 millions, this is lower than Intelgenx Technologies Corp 's recent average Revenue improvement of 28.34%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 119 other companies have achieved higher Revenue growth. While Intelgenx Technologies Corp ' s Revenue increase of 8.75% ranks overall at the positon no. 2429 in the first quarter 2024.


IGXT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 147.06 % -65.31 % -37.97 %
3rd Quarter September - 128.57 % -76.27 % 15.69 %
2nd Quarter June - -67.5 % 150 % 300 %
1st Quarter March 8.75 % -33.33 % -17.24 % 45 %
FY   - 8.42 % -37.91 % -

Financial Statements
Intelgenx Technologies 's first quarter 2024 Revenue $ 0.17 millions IGXT's Income Statement
Intelgenx Technologies 's first quarter 2023 Revenue $ 0.16 millions Quarterly IGXT's Income Statement


IGXT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 31.25 % 21.43 % -16.95 %
3rd Quarter September - 146.15 % -65 % 268.75 %
2nd Quarter June - -18.75 % 66.67 % -44.83 %
1st Quarter March -58.57 % -5.88 % -51.02 % -63.29 %
FY (Year on Year)   - 8.42 % -37.91 % -


Back to IGXT Growth rate Comparisons >> Back to IGXT Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #120
Healthcare Sector #326
Overall #2429

Revenue Y/Y Growth Statistics
High Average Low
484.18 % 28.34 % -81.01 %
(Sep 30 2021)   (Jun 30 2020)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #120
Healthcare Sector #326
Overall #2429
Revenue Y/Y Growth Statistics
High Average Low
484.18 % 28.34 % -81.01 %
(Sep 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Intelgenx Technologies 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
400643 % 19157.19 % -99.99 %
(Dec 31 2013)  


IGXT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Intelgenx Technologies Corp disclosed fall in Revenue from the fourth quarter by -58.57% to $ 0.17 millions, from $ 0.42 millions achived in the previous reporting period.

But that's not important problem, as Intelgenx Technologies 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 189 other companies have achieved higher Revenue quarter on quarter growth. While Intelgenx Technologies 's Revenue growth quarter on quarter, overall rank is 3481.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #510
Overall #3481
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #510
Overall #3481
Revenue Q/Q Growth Statistics
High Average Low
400643 % 19157.19 % -99.99 %
(Dec 31 2013)  


IGXT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Intelgenx Technologies Corp disclosed fall in Revenue from the fourth quarter by -58.57% to $ 0.17 millions, from $ 0.42 millions achived in the previous reporting period.

But that's not important problem, as Intelgenx Technologies 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 189 other companies have achieved higher Revenue quarter on quarter growth. While Intelgenx Technologies 's Revenue growth quarter on quarter, overall rank is 3481.


Intelgenx Technologies 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 1.04 $ 1.03 $ 0.79 $ 0.61 $ 0.88
Y / Y Revenue Growth (TTM) 19.09 % 8.42 % -38.16 % -64.58 % -41.12 %
Year on Year Revenue Growth Overall Ranking # 2859 # 2661 # 2186 # 206 # 35
Seqeuential Revenue Change (TTM) 1.17 % 31.04 % 28.85 % -30.29 % -7.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 2429 # 2426 # 2879 # 2749 # 684


Cumulative Revenue growth Comment
Although Intelgenx Technologies 's Annual Revenue growth year on year were below company's average 28.34% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 19.09% year on year, from 8.42% in Dec 31 2023.

In the Healthcare sector 370 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2661 to 2859.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 371
Overall # 2859

Revenue TTM Y/Y Growth Statistics
High Average Low
484.18 %
 28.34 %
-81.01 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 326
S&P 500 # 2429
Cumulative Revenue growth Comment
Although Intelgenx Technologies 's Annual Revenue growth year on year were below company's average 28.34% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 19.09% year on year, from 8.42% in Dec 31 2023.

In the Healthcare sector 370 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2661 to 2859.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 371
Overall # 2859

Revenue TTM Y/Y Growth Statistics
High Average Low
484.18 %
28.34 %
-81.01 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 326
S&P 500 # 2429




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IGXT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Electromed Inc 14.94%$ 14.940 millions
Volitionrx Limited14.50%$ 14.503 millions
Motus Gi Holdings Inc 14.29%$ 14.286 millions
Sonoma Pharmaceuticals Inc 14.10%$ 14.101 millions
Ensign Group Inc13.91%$ 13.907 millions
Boston Scientific Corporation13.81%$ 13.809 millions
Strata Critical Medical Inc 13.79%$ 13.790 millions
Iradimed Corporation13.72%$ 13.719 millions
Sanara Medtech Inc 13.69%$ 13.688 millions
Recursion Pharmaceuticals Inc 13.68%$ 13.681 millions
Senti Biosciences Holdings Inc 13.61%$ 13.608 millions
Universal Biosensors Inc 13.44%$ 13.435 millions
Encompass Health Corporation13.41%$ 13.409 millions
Novocure Limited13.36%$ 13.358 millions
Vertex Pharmaceuticals Inc13.30%$ 13.298 millions
Rigel Pharmaceuticals Inc13.29%$ 13.287 millions
Tandem Diabetes Care Inc 13.16%$ 13.159 millions
Quanterix Corporation12.97%$ 12.970 millions
Axogen inc 12.86%$ 12.857 millions
Option Care Health Inc 12.76%$ 12.763 millions
Rockwell Medical inc 12.58%$ 12.577 millions
Stablecoin Development Corporation12.48%$ 12.484 millions
Sotera Health Company12.48%$ 12.478 millions
Tango Therapeutics Inc 12.23%$ 12.227 millions
Vistagen Therapeutics Inc 12.10%$ 12.102 millions
Innovage Holding Corp 11.90%$ 11.900 millions
Lemaitre Vascular Inc 11.87%$ 11.875 millions
Biorestorative Therapies Inc 11.82%$ 11.821 millions
G1 Therapeutics Inc 11.82%$ 11.818 millions
Livanova Plc11.76%$ 11.758 millions


About Intelgenx Technologies Revenue Growth Rates (IGXT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intelgenx Technologies Corp (CIK 1098880).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001062993-24-010322
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intelgenx Technologies Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.